FAST NEWS: Junshi Biosciences Oral Covid Drug Wraps Up Trials, to Seek Sales Approval
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced late Monday that VV116, an oral drug developed by its JunTop Biosciences unit for the early treatment of Covid-19, has reached the main endpoint…
RELATED ARTICLES
-
Missing the Covid boat, Junshi stumbles back to old business
1877.HK 688180.SHG
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
FAST NEWS: Junshi Biosciences announces A-Share buyback
1877.HK 688180.SHG
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
Discover hidden China stock gems in our weekly newsletter